Biomarkers in heart failure

International Heart Journal

Volumn 55, Issue 6, 2014, Pages 474-481

  Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

BNP; Cystatin C; Galectin 3; H FABP; NT proBNP; Pentraxin 3; ST2; Troponin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; GALECTIN 3; GELATINASE B; INTERLEUKIN 18; MICRORNA; NEOPTERIN; PENTRAXIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPONIN; TUMOR NECROSIS FACTOR;

ARTICLE; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; KIDNEY FUNCTION TEST; METABOLISM; PHYSIOLOGICAL STRESS;

BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; INFLAMMATION; KIDNEY FUNCTION TESTS; MICRORNAS; STRESS, PHYSIOLOGICAL;

EID: 84919811772     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-267     Document Type: Article

References (80)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59. (Review)
2. Maisel A., Choudhary R. Biomarkers in acute heart failure--state of the art. Nat Rev Cardiol 2012; 9: 478-90. (Review)
3. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 303: H1085-H1095. (Review)
4. Choudhary R, Iqbal N, Khusro F, Higginbotham E, Green E, Maisel A. Heart failure biomarkers. J Cardiovasc Transl Res 2013; 6: 471-84. (Review)
5. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
6. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
7. Yu CM, Sanderson JE. Plasma brain natriuretic peptide--an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999; 1: 59-65.
8. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-41.
9. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-83.
10. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009; 158: 422-30.
11. Troughton R., Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
12. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013; 127: 500-7. (Review)
13. Desai AS. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation 2013; 127: 509-16.
14. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733-9.
15. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of aminoterminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011; 58: 1881-9.
16. Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 2010; 56: 2090-100.
17. Karlstrom P, Alehagen U, Boman K, Dahlstrom U; UPSTEPStudy Group. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011; 13: 1096-103.
18. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995; 214: 1175-83.
19. Pemberton CJ, Yandle TG, Rademaker MT, Charles CJ, Aitken GD, Espiner EA. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Am J Physiol 1998; 275: H1200-8.
20. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004; 90: 297-303.
21. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6.
22. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-6.
23. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107: 721-6.
24. Januzzi JL Jr, Peacock WF, Maisel A., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007; 50: 607-13.
25. Setsuta K, Seino Y, Takahashi N, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999; 84: 608-11.
26. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-74.
27. Peacock WF IV, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-26.
28. Lemos JA. Increasing sensitive assays for cardiac troponins: a review. JAMA 2013; 309: 2262-9. (Review)
29. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 1242-9.
30. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-12.
31. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: Incidence and clinical significance. Chest 2004; 125: 1877-84. (Review)
32. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011; 32: 404-11. (Review)
33. Nakamura Y, Yoshihisa A, Takiguchi M, et al. High-sensitivity cardiac troponin T predicts non-cardiac mortality in heart failure. Cir J 2014; 78: 890-5.
34. Glatz JF, Klein AH, van Nieuwenhoven FA, Hermens WT, van Dieijen-Visser MP, van Vusse GJ. Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 1994; 71: 135-40.
35. Arimoto T, Takeishi Y, Shiga R, et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 2005; 11: 56-60.
36. Niizeki T, Takeishi Y, Arimoto T, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 2007; 13: 120-7.
37. Niizeki T, Takeishi Y, Takabatake N, et al. Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Circ J 2007; 71: 1452-7.
38. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109: 2850-6.
39. Radauceanu A, Ducki C, Virion JM, et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008; 14: 467-74.
40. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-8.
41. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-24.
42. Lagorio S, Tagesson C, Forastiere F, Iavarone I, Axelson O, Carere A. Exposure to benzene and urinary concentrations of 8-hydroxydeoxyguanosine, a biological marker of oxidative damage to DNA. Occup Environ Med 1994; 51: 739-43.
43. Kobayashi S, Susa T, Tanaka T, et al. Urinary 8-hydroxy-2’-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 29-36.
44. Suzuki S, Shishido T, Ishino M, et al. 8-Hydroxy-2’-deoxyguanosine is a prognostic mediator for cardiac event. Eur J Clin Invest 2011; 41: 759-66.
45. Muller MM, Curtius HC, Herold M, Huber CH. Neopterin in clinical practice. Clin Chim Acta 1991; 201: 1-16. (Review)
46. Sasaki T, Takeishi Y, Suzuki S, et al. High serum level of neopterin is a risk factor of patients with heart failure. Int J Cardiol 2010; 145: 318.
47. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
48. Kinugawa T, Kato M, Yamamoto K, Hisatome I, Nohara R. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure. Int Heart J 2012; 53: 182-6.
49. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147: 931-8.
50. Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006; 151: 845-50.
51. Kamioka M, Suzuki H, Yamada S, Kamiyama Y, Saitoh S, Takeishi Y. High sensitivity C-reactive protein predicts nonresponders and cardiac deaths in severe heart failure patients after CRT implantation. Int Heart J 2012; 53: 306-12.
52. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994; 84: 3483-93.
53. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-66. (Review)
54. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81.
55. Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003; 60: S93-102. (Review)
56. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-9.
57. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-10.
58. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707. (Review)
59. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-60.
60. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142: 497-505.
61. Arimoto T, Takeishi Y, Niizeki T, et al. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail 2005; 11: 595-601.
62. Niizeki T, Takeishi Y, Arimoto T, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J 2005; 69: 922-7.
63. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2014; 2: 260-8.
64. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
65. Yang JA, Kato TS, Shulman BP, et al. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of Endstage Liver Disease (MELD) and MELD eXcluding INR (MELDXI) scoring system. J Heart Lung Transplant 2012; 31: 601-10.
66. Abe S, Yoshihisa A, Takiguchi M, et al. Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure. PLoS One 2014; 9: e100618.
67. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255-60.
68. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-8.
69. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
70. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-9.
71. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-54.
72. Tutarel O, Dangwal S, Bretthauer J, et al. Circulating miR-423 5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries. Int J Cardiol 2013; 167: 63-6.
73. Corsten MF, Dennert R, Jochems S, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 499-506.
74. Ellis KL, Cameron VA, Troughton R., Frampton CM, Ellmers LJ, Richards AM. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-47.
75. Cheng JM, Akkerhuis KM, Battes LC, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013; 15: 1350-62. (Review)
76. Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4: 246-56.
77. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60.
78. Kitahara T, Takeishi Y, Arimoto T, et al. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ J 2007; 71: 929-35.
79. Krum H, Elsik M, Schneider HG, et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011; 4: 561-8.
80. Ahmad T, Fiuzat M, Pencina MJ, et al. Charting a Roadmap for Heart Failure Biomarker Studies. JACC Heart Fail (in press)